Mounjaro cardiovascular outcomes: how to read the FDA indication and SURPASS-CVOT
The FDA added a cardiovascular indication for high-risk adults with type 2 diabetes. The trial compared tirzepatide with dulaglutide, an active treatment, and did not establish superiority.
The FDA approved Mounjaro to reduce the risk of cardiovascular death, nonfatal heart attack or nonfatal stroke in adults with type 2 diabetes at high risk for those events. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for the combined outcome; superiority was not established. The indication belongs to Mounjaro in the stated population. It is not a class-wide claim for anyone seeking weight loss.123
Read the indication and the enrollment rule separately
The FDA added the indication in August 2026. The label describes adults with type 2 diabetes at high risk for the specified cardiovascular events. The trial enrolled adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The trial tells you who generated the evidence; the indication tells you which use the FDA approved. Bring both distinctions to a consultation, particularly if a clinic is discussing a different brand or if the clinical history does not resemble the trial population.123
The comparator was already a treatment
The FDA label reports 803 first events among 6,647 treated participants assigned to Mounjaro (12.1%), compared with 863 among 6,647 assigned to dulaglutide (13.0%). The estimated hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. The trial met its prespecified noninferiority criterion. That means it ruled out a specified degree of worse performance against dulaglutide for the primary outcome. The numerical difference did not establish that Mounjaro was superior.23
The outcome counted the first occurrence of cardiovascular death, nonfatal heart attack or nonfatal stroke. The combined result does not establish a statistically confirmed advantage for each component. There was no untreated or placebo-only group in this comparison, so the two observed percentages cannot tell you what would have happened without either drug.23
| A claim you might hear | What to check |
|---|---|
| Heart indication | The exact brand, the type 2 diabetes requirement and the outcome named in the current label. |
| Better than comparator | Whether the trial established superiority or only met a noninferiority margin. |
| Better than Wegovy | Whether the studies enrolled similar people, used the same outcome and compared the same treatments. |
| My personal risk | Whether the number describes a trial group or an individual estimate. |
Ask what the two percentages would mean for the decision
An active-comparator trial is useful when a real decision is between established treatments. It can make a meaningful distinction even if the numbers look close. Here the primary result is about a first event during follow-up in a high-risk trial population. It does not predict how many events a particular patient will avoid or compare Mounjaro with not starting a medicine. Likewise, a number for weight or blood glucose is a different endpoint, even if it appears elsewhere in the same prescribing information.23
If the discussion is prompted by a cardiac event or a change in diabetes care, bring the diagnosis and current medication record. A prescriber can explain whether the consultation is for the new cardiovascular indication, for glycemic control or for a separate weight-management question. The medication name alone does not resolve those choices.12
The SELECT guide covers a different population and placebo comparison. If you are comparing medical weight management programs, ask who coordinates the diabetes, cardiovascular and weight goals, and which goal belongs to the specific prescription under discussion.23
Sources
- U.S. Food and Drug Administration. Mounjaro NDA 215866 S-044 and S-045 supplement approval. August 2026 supplement letter links the added indication to SURPASS-CVOT. Accessed .
- U.S. Food and Drug Administration. MOUNJARO (tirzepatide) prescribing information. Sections 1 and 14.6 establish the labeled population and the treated analysis counts. Accessed .
- New England Journal of Medicine / original randomized trial. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. Original trial record distinguishes noninferiority from superiority and identifies the active comparator. Accessed .